The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
Open accessAbstract
Recent breakthroughs in tumor immunotherapy such as immune checkpoint blockade (ICB) antibodies, have demonstrated the capacity of the immune system to fight cancer in a number of malignancies such as melanoma and lung cancer. The numbers, localization and phenotypes of tumor-infiltrating lymphocytes (TIL) are not only predictive of response to immunotherapy but also key modulators of disease progression. In this review, we focus on TIL profiling in cutaneous melanoma using histopathological approaches and highlight the observed prognostic value of the primary TIL subsets. The quantification of TIL in formalin-fixed tumor samples ranges from visual scoring of lymphocytic infiltrates in H&E to multiplex immunohistochemistry and immunofluorescence followed by enumeration using image analysis software. Nevertheless, TIL enumeration in the current literature primarily relies upon single marker immunohistochemistry analyses of major lymphocyte subsets such as conventional T cells (CD3, CD4, CD8), regulatory T cells (FOXP3) and B cells (CD20). We review key studies in the literature on associations between TIL subsets and patient survival. We also cover recent findings with respect to the existence of ectopic lymphoid aggregates found in the TME which are termed tertiary lymphoid structures (TLS) and are generally a positive prognostic feature. In addition to their prognostic significance, the existence of various TIL sub-populations has also been reported to predict a patient's response to ICB. Thus, the literature on the predictive potential of TIL subsets in melanoma patients receiving ICB has also been discussed. Finally, we describe recently developed state-of-the-art profiling approaches for tumor infiltrating immune cells such as digital pathology scoring algorithms (e.g., Immunoscore) and multiplex proteomics-based immunophenotyping platforms (e.g., imaging mass cytometry). Translating these novel technologies have the potential to revolutionize tumor immunopathology leading to altering our current understanding of cancer immunology and dramatically improving outcomes for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 5×
“Similar to the patients who responded to ipilimumab, most patients who responded to pembrolizumab also exhibited an increase in CD8 TIL from baseline (144).”
BackgroundMethodResultInfluentialCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Balch, C. M., Soong, S.-J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3622 · Cited by 2,388
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053 · cited 4×
“Subsequent immunofluorescent labeling of tissue sections from responding versus non-responding tumors with CD8 and TCF7 demonstrated that increased numbers of TCF7CD8 T cells were present in responders whereas increased TCF7CD8 T cells were present in non-responders (146).”
BackgroundInfluentialImmune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
Tertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Deep profiling of mouse splenic architecture with CODEX multiplexed imaging
Goltsev, Y., Samusik, N., Kennedy-Darling, J., Bhate, S., Hale, M., Vazquez, G., Black, S., & Nolan, G. P. (2018) · Cell · doi:10.1016/j.cell.2018.07.010 · Cited by 1,501 · cited 1×
“Co-detection by indexing (CODEX) is a multiplex fluorescence-based imaging approach which utilizes oligonucleotide conjugated antibodies (158, 164).”
BackgroundSchadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A., & Ugurel, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31559-9 · Cited by 1,488
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,360
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 1×
“Finally, studies have shown that checkpoint inhibitors can lead to the expansion of distinct TIL subsets, with anti-CTLA-4 and anti-PD-1 antibodies displaying differences effects on various lymphocyte subsets thereby leading to treatment-dependent shaping of the immune repertoire in tumors (147, 148).”
BackgroundModel Predicting Survival in Stage I Melanoma Based on Tumor Progression
Clark, W. H., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M., & Halpern, A. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1893 · Cited by 1,247
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
T cell subsets and their signature cytokines in autoimmune and inflammatory diseases
Raphael, I., Nalawade, S., Eagar, T. N., & Forsthuber, T. G. (2015) · Cytokine · doi:10.1016/j.cyto.2014.09.011 · Cited by 1,160
Saltz, J., Gupta, R., Hou, L., Kurc, T., Singh, P., Nguyen, V., Samaras, D., Shroyer, K. R., Zhao, T., Batiste, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.086 · Cited by 1,027
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
The Cancer Genome Atlas: Creating Lasting Value beyond Its Data
Hutter, C., & Zenklusen, J. C. (2018) · Cell · doi:10.1016/j.cell.2018.03.042 · Cited by 871
Azimi, F., Scolyer, R. A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S. W., Saw, R. P., & Thompson, J. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8539 · Cited by 856
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Chauvin, J.-M., Pagliano, O., Fourcade, J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 784
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Martínez-Lostao, L., Anel, A., & Pardo, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0685 · Cited by 717
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000162 · Cited by 709
Lin, J.-R., Izar, B., Wang, S., Yapp, C., Mei, S., Shah, P. M., Santagata, S., & Sorger, P. K. (2018) · eLife · doi:10.7554/elife.31657 · Cited by 692
Olkhanud, P. B., Damdinsuren, B., Bodogai, M., Gress, R. E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R. P., & Biragyn, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4316 · Cited by 684
Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
B cell regulation in cancer and anti-tumor immunity
Sarvaria, A., Madrigal, J. A., & Saudemont, A. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.35 · Cited by 630
Guidelines of care for the management of primary cutaneous melanoma
Bichakjian, C. K., Halpern, A. C., Johnson, T. M., Foote Hood, A., Grichnik, J. M., Swetter, S. M., Tsao, H., Barbosa, V. H., Chuang, T.-Y., Duvic, M., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.04.031 · Cited by 616
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Böttcher, J. P., & Reis e Sousa, C. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.09.001 · Cited by 607
Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T., Patterson, J. W., & Slingluff, C. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3218 · Cited by 590
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Sawant, D. V., Yano, H., Chikina, M., Zhang, Q., Liao, M., Liu, C., Callahan, D. J., Sun, Z., Sun, T., Tabib, T., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0346-9 · Cited by 543
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534 · cited 2×
“While baseline TIL scores in H&E stained biopsies were not elevated in patients who displayed clinical responses compared to those who did not, a majority of responding patients exhibited significant increases in TIL scores following treatment (139).”
BackgroundResultSharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A. A., Gnjatic, S., Bajorin, D. F., Reuter, V. E., Herr, H., Old, L. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611618104 · Cited by 526
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87324 · Cited by 525
Joshi, N. S., Akama-Garren, E. H., Lu, Y., Lee, D.-Y., Chang, G. P., Li, A., DuPage, M., Tammela, T., Kerper, N. R., Farago, A. F., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.006 · Cited by 520
Multiplexed protein maps link subcellular organization to cellular states
Gut, G., Herrmann, M. D., & Pelkmans, L. (2018) · Science · doi:10.1126/science.aar7042 · Cited by 510
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Durgeau, A., Virk, Y., Corgnac, S., & Mami-Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 495
Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer
Wouters, M. C. A., & Nelson, B. H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1481 · Cited by 495
Schalper, K. A., Velcheti, V., Carvajal, D., Wimberly, H., Brown, J., Pusztai, L., & Rimm, D. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2702 · Cited by 450
Coppola, D., Nebozhyn, M., Khalil, F., Dai, H., Yeatman, T., Loboda, A., & Mulé, J. J. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.03.007 · Cited by 434 · cited 1×
“Finally, a number of gene expression profiles, comprised of genes for key chemokines such as CCL19, CCL21 and CXCL13, or a combined TH1 and B cell signature, have been utilized to determine the presence of TLS in tumor tissues (111, 112).”
BackgroundB lymphocytes and cancer: a love-hate relationship
Yuen, G. J., Demissie, E., & Pillai, S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.010 · Cited by 433
Finkin, S., Yuan, D., Stein, I., Taniguchi, K., Weber, A., Unger, K., Browning, J. L., Goossens, N., Nakagawa, S., Gunasekaran, G., et al. (2015) · Nature Immunology · doi:10.1038/ni.3290 · Cited by 433
HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer
Barnes, T. A., & Amir, E. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.220 · Cited by 432
Messina, J. L., Fenstermacher, D. A., Eschrich, S., Qu, X., Berglund, A. E., Lloyd, M. C., Schell, M. J., Sondak, V. K., Weber, J. S., & Mulé, J. J. (2012) · Scientific Reports · doi:10.1038/srep00765 · Cited by 426
Perrot, I., Michaud, H.-A., Giraudon-Paoli, M., Augier, S., Docquier, A., Gros, L., Courtois, R., Déjou, C., Jecko, D., Becquart, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.091 · Cited by 423
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Drake, C. G., Lipson, E. J., & Brahmer, J. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.208 · Cited by 422
Quantifying tumor-infiltrating immune cells from transcriptomics data
Finotello, F., & Trajanoski, Z. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2150-z · Cited by 407
Stability and function of regulatory T cells expressing the transcription factor T-bet
Levine, A. G., Mendoza, A., Hemmers, S., Moltedo, B., Niec, R. E., Schizas, M., Hoyos, B. E., Putintseva, E. V., Chaudhry, A., Dikiy, S., et al. (2017) · Nature · doi:10.1038/nature22360 · Cited by 393
Trujillo, J. A., Sweis, R. F., Bao, R., & Luke, J. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0277 · Cited by 393
CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
Kim, H.-J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0216 · Cited by 380
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
Fridman, W. H., Galon, J., Pagès, F., Tartour, E., Sautès-Fridman, C., & Kroemer, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1316 · Cited by 380
The Immunoscore: Colon Cancer and Beyond
Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R., & Galon, J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1851 · Cited by 380
Sautès-Fridman, C., Lawand, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Dieu-Nosjean, M.-C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00407 · Cited by 379
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
Iglesia, M. D., Parker, J. S., Hoadley, K. A., Serody, J. S., Perou, C. M., & Vincent, B. G. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw144 · Cited by 360
DiLillo, D. J., Yanaba, K., & Tedder, T. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903009 · Cited by 359
The Emerging Role of B Cells in Tumor Immunity
Tsou, P., Katayama, H., Ostrin, E. J., & Hanash, S. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0431 · Cited by 345
From mice to humans: developments in cancer immunoediting
Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80004 · Cited by 337
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier, C., De Guillebon, E., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S., & Tartour, E. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000213 · Cited by 324
The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Hornyák, L., Dobos, N., Koncz, G., Karányi, Z., Páll, D., Szabó, Z., Halmos, G., & Székvölgyi, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00151 · Cited by 311
Moffitt, J. R., Hao, J., Bambah-Mukku, D., Lu, T., Dulac, C., & Zhuang, X. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617699113 · Cited by 308
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
Immuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 301
Chang, Q., Ornatsky, O. I., Siddiqui, I., Loboda, A., Baranov, V. I., & Hedley, D. W. (2017) · Cytometry Part A · doi:10.1002/cyto.a.23053 · Cited by 300
Taylor, R. C., Patel, A., Panageas, K. S., Busam, K. J., & Brady, M. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9755 · Cited by 297
Ladányi, A., Kiss, J., Somlai, B., Gilde, K., Fejős, Z., Mohos, A., Gaudi, I., & Tímár, J. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0286-3 · Cited by 287
Pantanowitz, L., Sharma, A., Carter, A. B., Kurc, T., Sussman, A., & Saltz, J. (2018) · Journal of Pathology Informatics · doi:10.4103/jpi.jpi_69_18 · Cited by 282
Jensen, T. O., Schmidt, H., Møller, H. J., Donskov, F., Høyer, M., Sjoegren, P., Christensen, I. J., & Steiniche, T. (2012) · Cancer · doi:10.1002/cncr.26511 · Cited by 281
Topography of cancer-associated immune cells in human solid tumors
Kather, J. N., Suarez-Carmona, M., Charoentong, P., Weis, C.-A., Hirsch, D., Bankhead, P., Horning, M., Ferber, D., Kel, I., Herpel, E., et al. (2018) · eLife · doi:10.7554/elife.36967 · Cited by 280
A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers
Camp, R. L., Neumeister, V., & Rimm, D. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3567 · Cited by 275
Fu, Q., Chen, N., Ge, C., Li, R., Li, Z., Zeng, B., Li, C., Wang, Y., Xue, Y., Song, X., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593806 · Cited by 274
Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases
Cipponi, A., Mercier, M., Seremet, T., Baurain, J.-F., Théate, I., van den Oord, J., Stas, M., Boon, T., Coulie, P. G., & van Baren, N. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1377 · Cited by 259
Colbeck, E. J., Ager, A., Gallimore, A., & Jones, G. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01830 · Cited by 252
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250 · cited 9×
“A comprehensive classification of TIL in H&E stained melanoma tissue has been available since 1989 (23).”
BackgroundInfluentialRole of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Badalamenti, G., Fanale, D., Incorvaia, L., Barraco, N., Listì, A., Maragliano, R., Vincenzi, B., Calò, V., Iovanna, J. L., Bazan, V., et al. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.013 · Cited by 247
Melanoma–stroma interactions: structural and functional aspects
Ruiter, D., Bogenrieder, T., Elder, D., & Herlyn, M. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00620-9 · Cited by 231
Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity
Engelhard, V. H., Rodriguez, A. B., Mauldin, I. S., Woods, A. N., Peske, J. D., & Slingluff, C. L. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701269 · Cited by 228
Hennequin, A., Derangère, V., Boidot, R., Apetoh, L., Vincent, J., Orry, D., Fraisse, J., Causeret, S., Martin, F., Arnould, L., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1054598 · Cited by 226
Buder-Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 217
Becht, E., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent-Puig, P., Zucman-Rossi, J., Dieu-Nosjean, M.-C., Sautès-Fridman, C., & Fridman, W. H. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213
Adoptive T-Cell Therapy for Cancer
Yang, J. C., & Rosenberg, S. A. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 206
Prognostic impact of B-cell density in cutaneous melanoma
Ladányi, A., Kiss, J., Mohos, A., Somlai, B., Liszkay, G., Gilde, K., Fejős, Z., Gaudi, I., Dobos, J., & Tímár, J. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1071-x · Cited by 199
Tregs: Where We Are and What Comes Next?
Zhao, H., Liao, X., & Kang, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01578 · Cited by 196
Park, Y.-J., Kuen, D.-S., & Chung, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0130-1 · Cited by 194
Martinet, L., Le Guellec, S., Filleron, T., Lamant, L., Meyer, N., Rochaix, P., Garrido, I., & Girard, J.-P. (2012) · OncoImmunology · doi:10.4161/onci.20492 · Cited by 193
The B-Side of Cancer Immunity: The Underrated Tune
Largeot, A., Pagano, G., Gonder, S., Moussay, E., & Paggetti, J. (2019) · Cells · doi:10.3390/cells8050449 · Cited by 180
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
Halse, H. M., Colebatch, A. J., Petrone, P., Henderson, M. A., Mills, J. K., Snow, H. A., Westwood, J. A., Sandhu, S. K., Raleigh, J., Behren, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28944-3 · Cited by 179
Cancer immune contexture and immunotherapy
Becht, É., Giraldo, N. A., Dieu‐Nosjean, M., Sautès‐Fridman, C., & Fridman, W. H. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.11.009 · Cited by 175
Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma
Ladányi, A. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12371 · Cited by 168
Piras, F., Colombari, R., Minerba, L., Murtas, D., Floris, C., Maxia, C., Corbu, A., Perra, M. T., & Sirigu, P. (2005) · Cancer · doi:10.1002/cncr.21283 · Cited by 168
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., Vlaeminck, Y. D., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 168
Cancer Immunotherapy: Beyond Checkpoint Blockade
Dougan, M. L., Dranoff, G., & Dougan, S. K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055552 · Cited by 164
Immune cell profiling in cancer: molecular approaches to cell-specific identification
Lyons, Y. A., Wu, S. Y., Overwijk, W. W., Baggerly, K., & Sood, A. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0031-0 · Cited by 153
Precision immunoprofiling by image analysis and artificial intelligence
Koelzer, V. H., Sirinukunwattana, K., Rittscher, J., & Mertz, K. D. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2485-z · Cited by 151
Lee, K. H., Kim, E. Y., Yun, J., Park, Y. L., Do, S., Chae, S. W., & Park, C. H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4832-5 · Cited by 142
Zappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Senbabaoglu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.009 · Cited by 142
van Houdt, I. S., Sluijter, B. J. R., Moesbergen, L. M., Vos, W., de Gruijl, T. D., Molenkamp, B. G., van den Eertwegh, A. J. M., Hooijberg, E., van Leeuwen, P. A. M., Meijer, C. J. L. M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23543 · Cited by 138
Figenschau, S. L., Fismen, S., Fenton, K. A., Fenton, C. G., & Mortensen, E. (2015) · BMC Cancer · doi:10.1186/s12885-015-1116-1 · Cited by 136
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 132
Svedman, F. C., Pillas, D., Kaur, M., Linder, R., Hansson, J., & Taylor, A. (2016) · Clinical Epidemiology · doi:10.2147/clep.s99021 · Cited by 127
Zappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Şenbabaoğlu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.007 · Cited by 127
Hofman, P. M., Badoual, C., Henderson, F., Berland, L., Hamila, M., Long-Mira, É., Lassalle, S., Roussel, H., Hofman, V., Tartour, É., et al. (2019) · Cancers · doi:10.3390/cancers11030283 · Cited by 127
Hillen, F., Baeten, C. I. M., van de Winkel, A., Creytens, D., van der Schaft, D. W. J., Winnepenninckx, V. J. L., & Griffioen, A. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0353-9 · Cited by 126
Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome
Garg, K., Maurer‐Granofszky, M., Griss, J., Brüggen, M., Wolf, I. H., Wagner, C., Willi, N., Mertz, K. D., & Wagner, S. N. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.03.022 · Cited by 126
Tumor-Infiltrating Lymphocytes in Melanoma
Lee, S. Y., & Margolin, K. A. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0257-5 · Cited by 124
Wang, K., Shen, T., Siegal, G. P., & Wei, S. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.09.012 · Cited by 123
Regulatory T‐cell heterogeneity and the cancer immune response
Ward‐Hartstonge, K. A., & Kemp, R. A. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.43 · Cited by 122 · cited 8×
“The recently observed diversity within Treg populations and the mechanisms through which Treg suppress immune responses have been reviewed elsewhere (76, 86, 87).”
BackgroundResultInfluentialT Helper 1 Cytokine mRNA Is Increased in Spontaneously Regressing Primary Melanomas
Lowes, M. A., Bishop, G. A., Crotty, K. A., Barnetson, R. S. C., & Halliday, G. M. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12292705 · Cited by 122
Tostivint, E. P., Latouche, A., Vaflard, P., Ricci, F., Loirat, D., Hescot, S., Sablin, M., Rouzier, R., Kamal, M. T., Morel, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00114 · Cited by 116
Parra, E. R., Francisco‐Cruz, A., & Wistuba, I. I. (2019) · Cancers · doi:10.3390/cancers11020247 · Cited by 115
Medler, T. R., Cotechini, T., & Coussens, L. M. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.07.008 · Cited by 109
Foxp3 expression in T regulatory cells and other cell lineages
Devaud, C., Darcy, P. K., & Kershaw, M. H. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1581-4 · Cited by 101
Mourmouras, V., BIAGIOLI, M., Miracco, C., Luzi, P., Tosi, P., Cosci, E., Monciatti, I., Mannucci, S., & Rubegni, P. (2007) · Oncology Reports · doi:10.3892/or.18.5.1115 · Cited by 100
Plasma cells in primary melanoma. Prognostic significance and possible role of IgA
Bosisio, F. M., Wilmott, J. S., Volders, N., Mercier, M., Wouters, J., Stas, M., Blokx, W. A. M., Massi, D., Thompson, J. F., Scolyer, R. A., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.28 · Cited by 94
Kakavand, H., Vilain, R. E., Wilmott, J. S., Burke, H., Yearley, J. H., Thompson, J. F., Hersey, P., Long, G. V., & Scolyer, R. A. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.110 · Cited by 91
Mihm, M. C., & Mulé, J. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0143 · Cited by 90
Histologic Classification of Tumor-Infiltrating Lymphocytes in Primary Cutaneous Malignant Melanoma
BUSAM, K. J., Antonescu, C. R., Marghoob, A. A., Nehal, K. S., Sachs, D. L., Shia, J., & Berwick, M. (2001) · American Journal of Clinical Pathology · doi:10.1309/g6ek-y6eh-0lgy-6d6p · Cited by 89
A user's perspective on GeoMxTM digital spatial profiling
Van, T. M., & Blank, C. U. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.05.001 · Cited by 85
Park, J. H., Powell, A. G. M. T., Roxburgh, C. S. D., Horgan, P. G., McMillan, D. C., & Edwards, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.17 · Cited by 84
Teillaud, J., & Dieu‐Nosjean, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00830 · Cited by 80
Balatoni, T., Mohos, A., Papp, E., Sebestyén, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., Gaudi, I., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2072-1 · Cited by 76
Ling, A., Lundberg, I. V., Eklöf, V., Wikberg, M. L., Öberg, Å., Edin, S., & Palmqvist, R. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.31 · Cited by 69
Unlocking the Complexities of Tumor-Associated Regulatory T Cells
Chao, J. L., & Savage, P. A. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701188 · Cited by 69
Ladányi, A., Mohos, A., Somlai, B., Liszkay, G., Gilde, K., Fejôs, Z., Gaudi, I., & Tı́már, J. (2010) · Pathology & Oncology Research · doi:10.1007/s12253-010-9254-x · Cited by 67
Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
Shevchenko, I., Mathes, A., Groth, C., Karakhanova, S., Müller, V. A., Utikal, J. S., Werner, J., Bazhin, A. V., & Umansky, V. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1744946 · Cited by 67
Baine, M. K., Turcu, G., Zito, C. R., Adeniran, A., Camp, R. L., Chen, L., Kluger, H. M., & Jilaveanu, L. B. (2015) · Oncotarget · doi:10.18632/oncotarget.4572 · Cited by 62
Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma
Knol, A., Nguyen, J., Quereux, G., Brocard, A., Khammari, A., & Dréno, B. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01260.x · Cited by 61
Turning the Tide Against Regulatory T Cells
Han, S., Toker, A., Liu, Z. Q., & Ohashi, P. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00279 · Cited by 60
Kurozumi, S., Inoue, K., Matsumoto, H., Fujii, T., Horiguchi, J., Oyama, T., Kurosumi, M., & Shirabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-018-38272-1 · Cited by 51
Takada, K., Kashiwagi, S., Goto, W., Asano, Y., Takahashi, K., Takashima, T., Tomita, S., Ohsawa, M., Hirakawa, K., & Ohira, M. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1460-4 · Cited by 50
Park, C. K., & Kim, S. K. (2017) · Oncotarget · doi:10.18632/oncotarget.14736 · Cited by 48
Regulatory Immune Mechanisms beyond Regulatory T Cells
Christoffersson, G., & von Herrath, M. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.005 · Cited by 46
Martinez‐Rodriguez, M., Thompson, A. K., & Monteagudo, C. C. (2014) · Histopathology · doi:10.1111/his.12437 · Cited by 43
Elder, D. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2504 · Cited by 43
Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma
Grotz, T. E., Jakub, J. W., Mansfield, A. S., Goldenstein, R., Enninga, E. A. L., Nevala, W. K., Leontovich, A. A., & Markovic, S. N. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026504 · Cited by 41
Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis
Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Semeraro, M., Jégou, S., Flores, C., Chen, L., Kwon, B. S., Borg, C., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2015.12.042 · Cited by 41
Modelling and investigation of the CD4+ T cells – Macrophages paradox in melanoma immunotherapies
Eftimie, R., & Hamam, H. (2017) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2017.02.022 · Cited by 40
Liu, C., Hu, Q., Hu, K., Su, H., Shi, F., Kong, L., Zhu, H., & Yu, J. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1872-9 · Cited by 40
Schnell, A., Schmidl, C., Herr, W., & Siska, P. J. (2018) · Biomedicines · doi:10.3390/biomedicines6010025 · Cited by 36
Jacquelot, N., Pitt, J. M., Enot, D. P., Roberti, M. P., Duong, C. P. M., Rusakiewicz, S., Eggermont, A. M. M., & Zitvogel, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1299303 · Cited by 30
Xu, Y., Chen, L., Xu, B., Xiong, Y., Yang, M., Rui, X., Shi, L., Wu, C., Jiang, J., & Lu, B. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000456600 · Cited by 26
Choice of first‐line therapy in metastatic melanoma
Gibney, G. T., & Atkins, M. B. (2019) · Cancer · doi:10.1002/cncr.31774 · Cited by 17
Cited by
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Dynamics and specificities of T cells in cancer immunotherapy
Oliveira, G., & Wu, C. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00560-y · Cited by 616
Ovarian Cancer Immunotherapy and Personalized Medicine
Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., & Nemunaitis, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126532 · Cited by 372
PD-1-stimulated T cell subsets are transcriptionally and functionally distinct
Lerrer, S., Tocheva, A. S., Bukhari, S., Adam, K., & Mor, A. (2021) · iScience · doi:10.1016/j.isci.2021.103020 · Cited by 19
Liu, Z., Dang, B., Wang, X., Liu, Y., Wang, C., & Lin, C. (2025) · Medical Oncology · doi:10.1007/s12032-025-03205-2
Metadata
- Authors
- Maibach, F., Sadozai, H., Seyed Jafari, S. M., Hunger, R. E., & Schenk, M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-10
- Volume
- 11
- Pages
- 2105-2105
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3085521743
- Cited by
- 312
- References
- 164
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.